A detailed history of Inceptionr LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Inceptionr LLC holds 12,951 shares of GILD stock, worth $1.22 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
12,951
Previous 5,604 131.1%
Holding current value
$1.22 Million
Previous $384 Million 182.4%
% of portfolio
0.27%
Previous 0.11%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$66.59 - $83.99 $489,236 - $617,074
7,347 Added 131.1%
12,951 $1.09 Billion
Q2 2024

Aug 13, 2024

SELL
$63.15 - $72.88 $570,055 - $657,887
-9,027 Reduced 61.7%
5,604 $384 Million
Q1 2024

May 09, 2024

BUY
$71.58 - $87.29 $565,696 - $689,852
7,903 Added 117.46%
14,631 $1.07 Billion
Q4 2023

Feb 08, 2024

SELL
$73.27 - $83.09 $119,649 - $135,685
-1,633 Reduced 19.53%
6,728 $545 Million
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $618,212 - $674,481
8,361 New
8,361 $627 Million
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $646,819 - $928,609
10,379 New
10,379 $891 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Inceptionr LLC Portfolio

Follow Inceptionr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Inceptionr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Inceptionr LLC with notifications on news.